Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia 42Leukemia, Lymphocytic, Chronic, B-Cell 41Lymphoma 30Myelodysplastic Syndromes 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Non-Hodgkin 18Hodgkin Disease 18Leukemia, Myeloid, Acute 17Multiple Myeloma 16Myeloproliferative Disorders 14Lymphoma, Mantle-Cell 10Lymphoma, Follicular 10Neoplasms, Plasma Cell 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, B-Cell, Marginal Zone 9Leukemia, Myeloid, Chronic-Phase 9Congenital Abnormalities 9Lymphoma, T-Cell, Peripheral 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Hematologic Neoplasms 8Burkitt Lymphoma 8Anemia, Aplastic 8Waldenstrom Macroglobulinemia 7Recurrence 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Large-Cell, Immunoblastic 7Primary Myelofibrosis 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 6Leukemia, Myeloid, Accelerated Phase 6

Interventions

Nivolumab 13Ipilimumab 10pembrolizumab 8cemiplimab 6Surveys and Questionnaires 6Biopsy 6aldesleukin 5Radiotherapy 5Interleukin-2 5Blood Specimen Collection 5Temozolomide 4Sirolimus 4Photochemotherapy 4Mohs Surgery 4HhAntag691 4Fluorouracil 4Educational Status 4Cyclophosphamide 4sonidegib 3fludarabine phosphate 3fludarabine 3avelumab 3Vemurafenib 3Surgical Procedures, Operative 3Radiation 3Petrolatum 3Cetuximab 3Aminolevulinic Acid 3trametinib 2dabrafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Skin Neoplasms × Alemtuzumab × Clear all
NCT06705608 2024-11-26

MS; FTY720

University of British Columbia

Completed
4,000 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Multiple Sclerosis, Skin Neoplasms, Multiple Sclerosis, Relapsing-Remitting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡